The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Johan Lochen, Erik Penser Bank. Phone: +46 8 463 80 00. Erik Penser Bank equity research

Felicia Rittemar, Vator Securities, Phone: +46 8 5333 2737. Vator Securities equity research

  Quarterly Report 3 21/22, June 22, 2022
In May we reported a significant milestone as the first patient was randomized in the precision medicine trial DIAGNODE-3 with Diamyd®. Approximately 20 clinics in Europe have so far been initiated and additional clinics and countries in Europe are underway.

In parallel, we are working diligently with the FDA with the aim to offer this important trial also to clinics and patients in the United States. As we aim to recruit the approximately 330 individuals with recent onset Type 1 Diabetes carrying the genetic HLA DR3-DQ2 haplotype...
The scientific rational and evidence supporting our therapeutic diabetes vaccine Diamyd® was further strengthened the past quarter with three articles published in peer-reviewed scientific journals.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
September 6 − September 7, 2022
LSX Nordic Congress
September 20 − September 23, 2022
EASD 2022
EASD 58th Annual Meeting, Stockholm, Sweden
October 5, 2022
Year-End Report
Year-End Report 2021/2022
November 10, 2022
Annual Report
Annual Report 2021/2022
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of June 30, 2022

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 10 329 750 13.43 10.34
Lindkvist, Bertil 6 240 000 8.11 6.24
Essen-Möller, Anders 556 223 2 813 040 4.38 8.38
Nordnet Pension 3 177 120 4.13 3.18
Essen-Möller, Maria-Teresa 400 000 963 998 1.77 4.97
Essen-Möller, Jon 400 000 631 275 1.34 4.63
Essenshaw, My 400 000 615 227 1.32 4.62
Hillborg, Erika 400 000 540 957 1.22 4.54
Esssen-Möller, Martin 400 000 361 120 0.99 4.36
Konstruktions o Försäljningsaktiebolag 725 000 0.94 0.73
Remaining shareholders 47 973 229 62.36 48.01
Total 2 556 223 74 370 716 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS